CIS 2020 Annual Meeting
  • Program
    • Annual Meeting Agenda
    • Pre-Conference Agenda
    • Networking and Additional Education Sessions
    • CIS Foundation Activities
  • Abstracts
    • Late-Breaking Abstracts
  • Attendees
    • Registration
    • Hotel Information
    • Patient Event
  • Exhibitors/Sponsors
    • Ancillary Meeting Request Form
  • Poster Presenter
    • Lightning Poster Information
  • Contact Us
  • CIS Website
  • Annual Meeting COVID-19 Information
Quick Links
  • www.clinimmsoc.org

Connect with us

CIS 2020 Annual Meeting

  • Program
    • Annual Meeting Agenda
    • Pre-Conference Agenda
    • Networking and Additional Education Sessions
    • CIS Foundation Activities
  • Abstracts
    • Late-Breaking Abstracts
  • Attendees
    • Registration
    • Hotel Information
    • Patient Event
  • Exhibitors/Sponsors
    • Ancillary Meeting Request Form
  • Poster Presenter
    • Lightning Poster Information
  • Contact Us
  • CIS Website
  • Annual Meeting COVID-19 Information

Pre-Conference Agenda

2020 Pre-Conference Education Day: Manage Like a Master - The Pros and Cons of Targeted Therapeutics
Thursday, April 2

8:00am - 2:30pm
 

8:00am-8:10am

Introduction

8:10am-8:35am

Use Of Checkpoint Inhibitor Therapy To Treat JC/BK Virus PML
Avindra Nath, MD, National Institutes of Health

8:35am-9:00am

Autoimmunity/Immune Dysregulation And Other Dark Sides Of Checkpoint Inhibitor Therapy

S. Lindsay Davis,  MD, University of Colorado School of Medicine

9:00am-9:25am

Anti-CD20 Therapies—Are There Differences Between the Old and the New?

Maria Leandro, MD, PhD, University College London

9:25am-9:50am

Occurrence Of PML After B Cell Depletion Therapy

Yang Mao-Draayer, MD, PhD, University of Michigan

9:50am-10:10am

Coffee Break

10:10am-10:35am

Anti-IFNgamma Therapy and HLH

Michael Jordan, MD, Cincinnati Children’s Hospital Medical Center

10:35am-11:00am

Natural History and Infections In Patients With Anti IFN-Gamma Autoantibodies

Christa Zerbe, MD, NIAID/NIH 

11:00am-11:25am

Use of Ruxolitinib to Treat HLH

Kim Nichols, MD, St. Jude Children's Research Hospital

11:25am-11:50am

Speaker TBD

11:50am-12:20pm

Lunch

12:20am-12:45pm

Use of mTOR Inhibitors To Treat Vascular Malformations

Joyce Teng, MD PhD, Stanford University

12:45pm-1:10pm

Use Of Eculizumab To Treat Myasthenia Gravis +/- Thymoma

James F. Howard Jr., MD, University of North Carolina

1:10pm-1:35pm

Infectious Risks Of Eculizumab Therapy

Lucy A. McNamara , PhD, National Center for Immunization and Respiratory Diseases, CDC

1:35pm-2:00pm


Speaker TBD

2:00pm-2:30pm


Speaker TBD

2:30pm-2:45pm

Break

Important Dates

Online Registration Closes
March 6

Housing Closes
March 10

ASGCT 2020

555 East Wells Street
Suite 1100
Milwaukee, WI 53202-3823 USA
Phone: (414) 224-8095
Fax: (414) 272-6070
Email: info@clinimmsoc.org

© 2023 Clinical Immunology Society. Legal Notices. Sunshine Act. Sitemap.